Dear Editors,

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread in more than 200 countries, infecting almost 2,000,000 patients to date and causing the Coronavirus \[[@CR2]\] (COVID-19) pandemic. There are recent reports indicating that COVID-19 patients commonly manifest olfactory and gustatory dysfunction even in the absence of rhinorrhea or nasal obstruction \[[@CR1]--[@CR4]\]. These preliminary observations are based on olfactory and gustatory questionnaires completed by patients and self-reported symptoms that are inherent to reporting bias and other limitations including reproducibility and validity. In addition, these reports included patients with minor COVID-19 symptoms and low-risk factor burden. In view of these considerations, we conducted a pilot case-control study using objective assessment of olfactory function with a standardized microencapsulated odor identification test.

We prospectively included laboratory-confirmed COVID-19 patients who were hospitalized because of pulmonary complications in the COVID-19 wards of a referral center in Athens ("Attikon" University Hospital) between March 19, 2020 and April 8, 2020. All cases included in the present study were diagnosed with COVID-19 using real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) from upper respiratory samples. In detail, nasopharyngeal and/or oropharyngeal swabs were collected and transferred to the Clinical Microbiology laboratory, immersed in an appropriate virus transport medium (e.g. UTM Viral Transport, Copan Diagnostics Inc., Brescia, Italy). Flocked swabs made from synthetic material were preferred for sample collection to maximize viral recovery. Lower respiratory tract samples (e.g. bronchoalveolar lavage or aspirates, sputum, etc.) were also accepted. Automated purification of viral RNA from either viral transport medium or lower respiratory tract samples was performed using the QIAsymphony DSP virus/pathogen mini-kit on the QIAsymphony SP platform (QIAGEN, Hilden, Germany). A Real-Time, one-step Reverse Transcription---PCR, specific for ORF1ab gene of SARS-CoV-2 and for N gene of all, or other coronaviruses was finally performed on the Rotor-Gene Q MDx thermocycler (QIAGEN, Hilden, Germany), using the VIASURE SARS-CoV-2 Real-Time PCR Detection Kit (CerTest Biotec SL, Zaragoza, Spain).

We excluded patients (i) who reported olfactory disorder prior to the onset of COVID-19 respiratory symptoms, (ii) who reported a history of movement disorders, and (iii) patients who declined olfactory function testing. The very brief smell identification test (three-odorant test) chosen for this study was the Quick Smell Identification Test (Q-SIT; Sensonics, Inc.,Haddon Heights, NJ) and was selected on the basis of cost, convenience, format, standardization, and validation \[[@CR5]\]. Q-SIT consists of individual 5 × 5.5 inch tear-out cards, each of which contains three microencapsulated odorant strips. Beside each strip is a multiple-choice question with five \[[@CR5]\]. The Q-SIT score was computed by the sum of correct responses and ranges between 0 (anosmia) and 3 (normosmia). Q-SIT score values of 1 and 2 correspond to moderate/severe microsomia and mild microsomia \[[@CR5]\]. We also evaluated nasal congestion using the SinoNasal Outcome Test 22 (SNOT 22) questionnaire that has been validated for use in Greek language \[[@CR6]\].

Controls included age- and sex-matched individuals who presented to Neurological Outpatient Clinic before COVID-19 outbreak (February 2020) in Greece with potential movement disorder symptoms and underwent evaluation of olfactory function using Q-SIT. The clinical diagnosis of Parkinson\'s Disease and other movement disorders were excluded in controls. All control patients were not hospitalized and were not affected by COVID-19. No control patient had influenza and common cold symptoms at the time of testing (January 2019-December 2019).

We included a total of 22 cases (mean age 55 ± 10 years, 57% men) and 22 age- and sex-matched controls. The baseline characteristics of the cases are summarized in Table [1](#Tab1){ref-type="table"}. The median number of risk factors in cases was 1 \[interquartile range (IQR) 0--2)\] and the median number of elapsed days between hospital admission and olfactory testing was 12 (IQR 9--15). The median Q-SIT score was lower (*p* = 0.004) in cases (2, IQR: 1--2) than controls (3, IQR: 2--3; Fig. [1](#Fig1){ref-type="fig"}). The prevalence of normosmia (*p* = 0.006) was lower in cases (23%) than controls (64%). Gustatory dysfunction was very commonly or continuously self-reported in 23% of cases. Among the 16 cases with microsomia (*n* = 15) and anosmia (*n* = 1), nasal congestion was identified on SNOT 22 questionnaire in three patients. After excluding these three cases, the lower prevalence of normosmia persisted in cases (26%) compared to controls (64%, *p* = 0.017) No patient with COVID-19 was intubated or died during their hospitalization.Table 1Baseline characteristics of cases (*n* = 22)VariableAge, years (mean ± SD)55 ± 10Male sex, %57%Hypertension, %57%Diabetes mellitus, %22%Atrial fibrillation, %13%Ischemic heart disease, %Previous stroke, %13%0%Smoking, %Median number of risk factors (IQR)Median numbers of days between symptom onset and olfactory assessment (IQR)13%1 (0--2)12 (9--15)History of nose surgery, %9%\*History of chronic sinusitis, %5%History of allergic rhinitis, %14%*IQR* interquartile rangeFig. 1Distribution of Q-SIT scores in cases and controls. Q-SIT scores ranged between 0 and 3 according to the number of correct answers. Statistical comparison between the two groups was performed using the Cochran-Mantel--Haenszel test. ^\*^﻿Nasal septum surgery in 2016 (*n* = 1), rhinoplasty in 2014 (*n* = 1). IQR: interquartile range.

The present study adds to the preliminary evidence provided by Moen et al. indicating that objectively assessed olfactory function may be impaired in COVID-19 hospitalized patients \[[@CR7]\]. The findings of our pilot study highlight that moderate olfactory dysfunction was identified in approximately three-quarters of hospitalized COVID-19 patients using an objective smelling identification test. Olfactory dysfunction was more prevalent in cases than controls even after controlling for nasal congestion symptoms. These findings lend support to the accruing literature underscoring olfactory dysfunction as a prevalent symptom of COVID-19 disease that should be systematically evaluated \[[@CR3], [@CR3]\]. The potential movement of SARS-CoV-2 to the brain via the cribriform plate close to the olfactory bulb may represent a pathway enabling the virus to reach and affect the central nervous system that deserves further investigation \[[@CR8]\].

Certain limitations of the present report should be highlighted including the small sample size, the lack of follow-up on the evolution of olfactory dysfunction, and the non-inclusion of patients hospitalized in the Intensive Care Unit of our Institution. Another limitation is related to the lack of endoscopic/objective nasal examination to exclude the presence of unknown chronic rhinitis and nasal polyps. In brief, the present case-control study conducted in Greece coupled with the findings of a similar case-control study conducted in Iran \[[@CR7]\] underscores that COVID-19 disease in hospitalized patients is commonly associated with microsomia that may be objectively assessed and quantified.
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